Overview

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Status:
Unknown status

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label prospective randomized pharmacodynamic investigation of two anti platelet regimens in patients who are planned to undergo PCI for non-ST segment elevation acute coronary syndrome(NSTE-ACS) for 24 hours 1. Ticagrelor : loading dose(180mg) followed by maintenance dose(90mg bid) 2. Tirofiban : 0.4ug/kg/min for 30min followed by 0.1ug/kg/min - both agents will be given on top of aspirin

Phase:

Phase 3

Details

Lead Sponsor:

Pusan National University Yangsan Hospital

Collaborator:

AstraZeneca

Treatments:

Ticagrelor
Tirofiban